199 results
8-K
EX-10.2
SEEL
Seelos Therapeutics Inc
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
incurred with the investigation, preparation and prosecution of such action or proceeding.
-7-
SECTION 11. ENTIRE AGREEMENT/MISCELLANEOUS
8-K
EX-10.1
SEEL
Seelos Therapeutics Inc
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
hereto.
“Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial … . Except as set forth on Schedule 3.1(j), there is no action, suit, inquiry, notice of violation, proceeding or investigation pending
8-K
EX-4.2
ta1jw2agp iyz
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
8-K
EX-5.2
aqdz3c
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
8-K
EX-4.1
ebogqf1b
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
8-K
EX-1.1
4c55t4811qsdznamo 9f
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
424B5
1kua 558qpy
30 Nov 23
Prospectus supplement for primary offering
4:58pm
424B5
9oo7wvdubmm
28 Nov 23
Prospectus supplement for primary offering
4:06pm
8-K
EX-5.2
9zir2hde38dbf
25 Sep 23
Entry into a Material Definitive Agreement
4:06pm
8-K
EX-10.1
w4ma 4qnxw00pl
25 Sep 23
Entry into a Material Definitive Agreement
4:06pm
8-K
EX-4.1
sypwsq18u 7z5w
25 Sep 23
Entry into a Material Definitive Agreement
4:06pm
424B5
cpwd8 bi731f4w8bua
25 Sep 23
Prospectus supplement for primary offering
6:02am